Corcept Therapeutics Incorporated (CORT)
Automate Your Wheel Strategy on CORT
With Tiblio's Option Bot, you can configure your own wheel strategy including CORT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CORT
- Rev/Share 6.5841
- Book/Share 6.5634
- PB 10.8755
- Debt/Equity 0.01
- CurrentRatio 3.065
- ROIC 0.1297
- MktCap 7569492100.0
- FreeCF/Share 1.7018
- PFCF 42.7261
- PE 55.9338
- Debt/Assets 0.0081
- DivYield 0
- ROE 0.2046
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting
Published: June 05, 2025 by: Business Wire
Sentiment: Neutral
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, presented results from its DAZALS study of dazucorilant in patients with ALS at the European Network to Cure ALS (ENCALS) 2025 annual meeting. The presentation can be found here. DAZALS is a randomi.
Read More
CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Neutral
Corcept's first-quarter 2025 earnings meet estimates while revenues miss the same. The company reiterates its revenue guidance for 2025.
Read More
Corcept Therapeutics Incorporated (CORT) Q1 2025 Earnings Call Transcript
Published: May 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q1 2025 Earnings Conference Call May 5, 2025 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Sean Maduck - President, Endocrinology Charlie Robb - Chief Business Officer Joe Belanoff - Chief Executive Officer Roberto Vieira - President, Oncology Bill Guyer - Chief Development Officer Conference Call Participants Edward Nash - Canaccord David Amsellem - Piper Sandler Joon Lee - Truist Securities RK - H. C. Wainwright Operator Thank you for standing by.
Read More
CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025
Published: April 23, 2025 by: Business Wire
Sentiment: Neutral
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, will present data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the 2025 American Society of Clinical Oncology (ASC.
Read More
Does Corcept (CORT) Have the Potential to Rally 28.63% as Wall Street Analysts Expect?
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 28.6% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release
Published: April 01, 2025 by: Seeking Alpha
Sentiment: Positive
Corcept Therapeutics Incorporated's relacorilant met the primary endpoint in the phase 3 ROSELLA study for platinum-resistant ovarian cancer patients, boosting shares by over 90% the very same day. Upcoming catalysts include full trial data release at a medical conference, NDA filing in Q3 2025, and MAA submission to the EMA shortly afterward. Relacorilant also targets hypercortisolism with endogenous Cushing's Syndrome patients with an FDA PDUFA date set for December 30, 2025, based on positive GRACE, GRADIENT, and phase 2 study data.
Read More
CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal
Published: April 01, 2025 by: Zacks Investment Research
Sentiment: Positive
The ROSELLA study evaluating Corcept's relacorilant plus nab-paclitaxel for treating patients with platinum-resistant ovarian cancer meets the primary endpoint.
Read More
Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar?
Published: April 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read More
Here's Why Momentum in Corcept (CORT) Should Keep going
Published: April 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Corcept (CORT) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Read More
Corcept Therapeutics shares surge on positive late-stage ovarian cancer trial results
Published: March 31, 2025 by: Proactive Investors
Sentiment: Positive
Corcept Therapeutics (NASDAQ:CORT) shares surged more than 85% after the company announced positive results from its Phase 3 ROSELLA trial, evaluating relacorilant combined with nab-paclitaxel in patients with platinum-resistant ovarian cancer, that will support regulatory applications in the US and Europe. The trial met its primary endpoint, demonstrating a 30% reduction in the risk of disease progression compared to nab-paclitaxel alone.
Read More
Why Is Corcept (CORT) Down 5.3% Since Last Earnings Report?
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Negative
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
Read More
Is Corcept Therapeutics (CORT) Stock Outpacing Its Medical Peers This Year?
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Corcept Therapeutics (CORT) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Read More
Shareholders that lost money on Corcept Therapeutics Incorporated(CORT) should contact Levi & Korsinsky about Securities Fraud Investigation - CORT
Published: March 18, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated") (NASDAQ:CORT) concerning possible violations of federal securities laws. August 2020, Teva Pharmaceutical Industries Limited ("Teva") received approval from the U.S. Food and Drug Administration to market an off-patent version of Korlym, a best-selling Corcept product.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
Published: March 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ:CORT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Bronstein, Gewirtz & Grossman, LLC (CORT) Investors to Inquire about Securities Investigation
Published: March 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ:CORT). Investors who purchased Corcept securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CORT.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Corcept Therapeutics Incorporated (CORT) Shareholders to Inquire about Securities Investigation
Published: March 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ:CORT). Investors who purchased Corcept securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CORT.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating Corcept Therapeutics Incorporated (CORT) And Encourages Shareholders to Connect
Published: March 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ:CORT). Investors who purchased Corcept securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CORT.
Read More
Corcept Shares Rise More Than 55% in 6 Months: Here's Why
Published: March 07, 2025 by: Zacks Investment Research
Sentiment: Positive
CORT's Cushing's syndrome drug, Korlym, is driving revenues. The FDA's acceptance of the NDA for relacorilant also bodes well.
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Corcept Therapeutics Incorporated (CORT) and Encourages Shareholders to Learn More About the Investigation
Published: March 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ:CORT). Investors who purchased Corcept securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CORT.
Read More
Corcept Therapeutics Incorporated (CORT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Published: March 06, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ:CORT). Investors who purchased Corcept securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CORT.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
Published: March 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ:CORT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating Corcept Therapeutics Incorporated (CORT) And Encourages Investors to Connect
Published: March 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ:CORT). Investors who purchased Corcept securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CORT.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Corcept Therapeutics Incorporated (CORT) Stockholders to Inquire about Securities Investigation
Published: March 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ:CORT). Investors who purchased Corcept securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CORT.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
Published: March 03, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
3 Reasons Why Growth Investors Shouldn't Overlook Corcept (CORT)
Published: February 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Corcept (CORT) possesses solid growth attributes, which could help it handily outperform the market.
Read More
Why Corcept Therapeutics (CORT) is a Top Growth Stock for the Long-Term
Published: February 28, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Corcept Therapeutics Incorporated (CORT) Investors to Inquire about Securities Investigation
Published: February 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ:CORT). Investors who purchased Corcept securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CORT.
Read More
CORT's Q4 Earnings and Revenues Fall Short of Estimates
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Negative
Corcept reports weaker-than-expected results for the fourth quarter of 2024. Korlym drives year-over-year sales.
Read More
Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Corcept Therapeutics, Inc. (CORT) Q4 2024 Earnings Call Transcript
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral
Corcept Therapeutics, Inc. (NASDAQ:CORT ) Q4 2024 Earnings Conference Call February 26, 2025 5:00 PM ET Company Participants Atabak Mokari - CFO & Treasurer Gary Robb - Chief Business Officer & Secretary Joe Belanoff - Co-Founder, President, CEO & Director Bill Guyer - Chief Development Officer Sean Maduck - President, Endocrinology Conference Call Participants David Amsellem - Piper Sandler Swayampakula Ramakanth - H.C. Wainwright Asim Rana - Truist Operator Thank you for standing by, and welcome to Corcept Therapeutics conference call.
Read More
About Corcept Therapeutics Incorporated (CORT)
- IPO Date 2004-04-14
- Website https://www.corcept.com
- Industry Biotechnology
- CEO Dr. Joseph K. Belanoff M.D.
- Employees 500